Keck School of Medicine of the University of Southern California.
Arthroscopy. 2020 May;36(5):1321-1322. doi: 10.1016/j.arthro.2020.02.019.
The use of regenerative technologies including mesenchymal stromal cells, also known as connective tissue progenitors (CTPs), has gained tremendous popularity as a primary and adjuvant treatment for many musculoskeletal conditions. The concentration of bone marrow-derived CTPs delivered to the site of injury has been directly correlated to the therapeutic effect in the setting of rotator cuff repair and the healing of long-bone fractures. In addition, there has been some limited in vitro and in vivo evidence to suggest that the delivery of bone marrow-derived CTPs may improve cartilage regeneration. Bone marrow aspirate concentrate harvested from the body of the ilium during hip arthroscopy yields a CTP concentration that is commensurate with other conventional donor sites and appears to be safe. However, the clinical benefit and financial cost associated with the delivery of bone marrow aspirate concentrate to the hip joint at the time of acetabular labral repair remains unclear at best and should be approached with caution.
再生技术的应用，包括间充质基质细胞，也称为结缔组织祖细胞（CTPs），已作为许多肌肉骨骼疾病的主要和辅助治疗方法而受到广泛关注。在肩袖修复和长骨骨折的治疗中，损伤部位输送的骨髓源性 CTPs 的浓度与治疗效果直接相关。此外，有一些有限的体外和体内证据表明，输送骨髓源性 CTPs 可能改善软骨再生。在髋关节镜检查期间从髂骨体采集的骨髓抽吸浓缩物可获得与其他常规供体部位相当的 CTP 浓度，并且似乎是安全的。然而，在髋臼唇修复时将骨髓抽吸浓缩物输送到髋关节的临床益处和经济成本尚不清楚，最好谨慎对待。
